Provided by Tiger Trade Technology Pte. Ltd.

Inhibikase Therapeutics, Inc.

2.00
+0.07003.63%
Post-market: 2.000.00000.00%19:30 EDT
Volume:434.46K
Turnover:860.85K
Market Cap:280.00M
PE:-4.62
High:2.02
Open:1.96
Low:1.93
Close:1.93
52wk High:2.61
52wk Low:1.33
Shares:140.00M
Float Shares:64.52M
Volume Ratio:0.81
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4327
EPS(LYR):-0.4909
ROE:-51.96%
ROA:-32.79%
PB:1.83
PE(LYR):-4.07

Loading ...

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
17 hours ago

Inhibikase advances IKT-001 in pivotal PAH Phase 3

TIPRANKS
·
Sep 09

Inhibikase Therapeutics Replaces Auditor CohnReznick with Deloitte

Reuters
·
Aug 27

Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth

TIPRANKS
·
Aug 13

Inhibikase Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Inhibikase Therapeutics (IKT)

TIPRANKS
·
Aug 12

Inhibikase Therapeutics Q2 EPS $(0.11), Inline

Benzinga Earnings
·
Aug 12

Inhibikase Rugi Bersih Q2 FY26 Melebar Jadi USD 19,6 Juta; Belanja R&D Melonjak 153,9% Jadi USD 13,4 Juta

Reuters
·
Aug 12

Inhibikase Q2 Net Loss Widens on Higher R&D, SG&A Costs

Reuters
·
Aug 12

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

THOMSON REUTERS
·
Aug 12

Inhibikase Therapeutics Q2 EPS USD -0.11

THOMSON REUTERS
·
Aug 12

Inhibikase Therapeutics, Inc. Expected to Post a Loss of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Inhibikase Swaps 18,030,000 Shares for RA Capital Pre-funded Warrant in Unregistered Offering

Reuters
·
Jul 30

Inhibikase Wins FDA Orphan Drug Designation for Ikt-001 in PAH

Reuters
·
Jul 23

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to Ikt-001 for the Treatment of Pah

THOMSON REUTERS
·
Jul 23

RA Capital Management Files Initial Beneficial Ownership Statement in Inhibikase Therapeutics

Reuters
·
Jul 18

Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation

TIPRANKS
·
Jul 17

Inhibikase raises $50M to fund PAH program

TIPRANKS
·
Jul 15

Inhibikase Therapeutics Shares Rise on $50M At‑the‑market Share Sale

Dow Jones
·
Jul 14

Inhibikase Therapeutics Sells 25,000,000 Shares Via ATM for Gross Proceeds of $50 Million

Reuters
·
Jul 14